|Country||Switzerland - SIR Ranking of Switzerland||
|Subject Area and Category||Biochemistry, Genetics and Molecular Biology|
|Publisher||Frontiers Media S.A.|
|Scope||The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.|
|Join the conversation about this journal|
The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.
The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.
This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.
|Cites per document||Year||Value|
|Cites / Doc. (4 years)||2013||0.000|
|Cites / Doc. (4 years)||2014||1.000|
|Cites / Doc. (4 years)||2015||3.457|
|Cites / Doc. (4 years)||2016||3.341|
|Cites / Doc. (4 years)||2017||4.101|
|Cites / Doc. (4 years)||2018||4.534|
|Cites / Doc. (3 years)||2013||0.000|
|Cites / Doc. (3 years)||2014||1.000|
|Cites / Doc. (3 years)||2015||3.457|
|Cites / Doc. (3 years)||2016||3.341|
|Cites / Doc. (3 years)||2017||4.114|
|Cites / Doc. (3 years)||2018||4.443|
|Cites / Doc. (2 years)||2013||0.000|
|Cites / Doc. (2 years)||2014||1.000|
|Cites / Doc. (2 years)||2015||3.457|
|Cites / Doc. (2 years)||2016||3.347|
|Cites / Doc. (2 years)||2017||3.970|
|Cites / Doc. (2 years)||2018||4.212|
Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years.
Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.
Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.
|External Cites per document||2013||0|
|External Cites per document||2014||1.000|
|External Cites per document||2015||3.143|
|External Cites per document||2016||3.313|
|External Cites per document||2017||4.087|
|External Cites per document||2018||4.349|
|Cites per document||2013||0.000|
|Cites per document||2014||1.000|
|Cites per document||2015||3.457|
|Cites per document||2016||3.341|
|Cites per document||2017||4.114|
|Cites per document||2018||4.443|
International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.
Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.
Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.